What Is ARA-290?
ARA-290, also known as cibinetide, is a synthetic peptide derived from erythropoietin (EPO). Unlike EPO, it is designed to activate the innate repair receptor without significantly stimulating red blood cell production. Researchers are studying it for tissue protection, nerve repair, and chronic inflammatory conditions.
How It Works
ARA-290 selectively targets the innate repair receptor (IRR), a receptor complex involved in reducing inflammation and promoting tissue healing after injury. Activation of this pathway may reduce inflammatory signaling, protect nerves, and support recovery without the hematologic effects associated with erythropoietin.
Potential Benefits Being Studied
Research has evaluated ARA-290 for small fiber neuropathy, chronic neuropathic pain, sarcoidosis-related nerve injury, diabetes-related complications, wound healing, kidney injury, autoimmune disease, and tissue protection following ischemic injury. Human clinical trials have shown encouraging but still evolving results.
Typical Research Dosing
There is no universally accepted dosing regimen. Clinical studies have investigated subcutaneous administration using protocols specific to the condition under evaluation.
Administration and Timing
Most published human studies have used subcutaneous injection. Frequency and treatment duration vary depending on the clinical trial design.
Possible Side Effects
ARA-290 has generally been well tolerated in clinical studies. Reported adverse effects include mild injection-site reactions, headache, dizziness, nausea, and fatigue. Unlike erythropoietin, it has not demonstrated significant increases in red blood cell production in research settings.
Contraindications and Precautions
Although safety has been favorable in published studies, ARA-290 remains investigational for many indications. Individuals with significant medical conditions should discuss therapies affecting inflammatory and repair pathways with a qualified healthcare professional.
Bottom Line
ARA-290 is one of the more promising regenerative peptides because it focuses on reducing inflammation while promoting tissue repair through the innate repair receptor. Ongoing clinical trials continue to define its role in neuropathy, chronic pain, and regenerative medicine.
Educational Reminder
This document is intended for educational purposes only and summarizes current research. It should not replace individualized medical advice.